Biglycan Deficiency Interferes with Ovariectomy-Induced Bone Loss

Journal of Bone and Mineral Research

Volumn 18, Issue 12, 2003, Pages 2152-2158

  Nielsen, Karina L ^a,b   Allen, Matthew R ^c   Bloomfield, Susan A ^c   Andersen, Thomas L ^a   Chen, Xiao Dong ^d   Poulsen, Hans S ^b   Young, Marian F ^d   Heegaard, Anne Marie ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c TEXAS A AND M UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Biglycan; Bone turnover; Deficient mice; Osteopenia; Ovariectomy

Indexed keywords

BIGLYCAN; DEOXYPYRIDINOLINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL MODEL; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PROTEIN DEFICIENCY; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; TRABECULAR BONE; WILD TYPE;

ANIMALS; BONE DENSITY; CARRIER PROTEINS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; OVARIECTOMY; PROTEOGLYCANS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0344874614     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.12.2152     Document Type: Conference Paper

References (42)

1. Matsushima N, Ohyanagi T, Tanaka T, Kretsinger RH 2000 Supermotifs and evolution of tandem leucine-rich repeats within the small proteoglycans-biglycan, decorin, lumican, fibromodulin, PRELP, keratocan, osteoadherin, epiphycan, and osteoglycin. Proteins 38:210-225.
2. Iozzo RV, Murdoch AD 1996 Proteoglycans of the extracellular environment: Clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 10:598-614.
3. Iozzo RV 1999 The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 274:18843-18846.
4. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG 1990 Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 38:1549-1563.
5. Hocking AM, Shinomura T, McQuillan DJ 1998 Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 17:1-19.
6. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, Border WA, Ruoslahti E 1994 Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302:527-534.
7. Schonherr E, Witsch-Prehm P, Harrach B, Robenek H, Rauterberg J, Kresse H 1995 Interaction of biglycan with type I collagen. J Biol Chem 270:2776-2783.
8. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, Goldstein S, Bonadio J, Boskey A, Heegaard AM, Sommer B, Satomura K, Dominguez P, Zhao C, Kulkarni AB, Robey PG, Young MF 1998 Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 20:78-82.
9. Chen XD, Shi S, Xu T, Robey PG, Young MF 2002 Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J Bone Miner Res 17:331-340.
10. Corsi A, Xu T, Chen XD, Boyde A, Liang J, Mankani M, Sommer B, Iozzo RV, Eichstetter I, Robey PG, Bianco P, Young MF 2002 Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res 17:1180-1189.
11. Geerkens C, Vetter U, Just W, Fedarko NS, Fisher LW, Young MF, Termine JD, Robey PG, Wohrle D, Vogel W 1995 The X-chromosomal human biglycan gene BGN is subject to X inactivation but is transcribed like an X-Y homologous gene. Hum Genet 96:44-52.
12. McBride OW, Fisher LW, Young MF 1990 Localization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xq13-qter and 12q, respectively. Genomics 6:219-225.
13. Bernhards J, Weitzel B, Werner M, Rimpler M, Georgii A 1992 A new histological embedding method by low-temperature polymerisation of methyl methacrylate allowing immuno- and enzyme histochemical studies on semi-thin sections of undecalcified bone marrow biopsies. Histochemistry 98:145-154.
14. Gruber HE 1992 Adaptations of Goldner's Masson trichrome stain for the study of undecalcified plastic embedded bone. Biotech Histochem 67:30-34.
15. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
16. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP 1999 Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274:13613-13618.
17. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
18. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T 1999 Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand. Bone 25:517-523.
19. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT 1999 Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25:525-534.
20. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T 2000 Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484.
21. Young MF, Kerr JM, lbaraki K, Heegaard AM, Robey PG 1992 Structure, expression, and regulation of the major noncollagenous matrix proteins of bone. Clin Orthop 281:275-294.
22. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R 2002 Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30:18-25.
23. Oz OK, Zerwekh JE, Fisher C, Graves K, Nanu L, Millsaps R, Simpson ER 2000 Bone has a sexually dimorphic response to aromatase deficiency. J Bone Miner Res 15:507-514.
24. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT 1998 Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101-1111.
25. Yoshitake H, Rittling SR, Denhardt DT, Noda M 1999 Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 96:8156-8160.
26. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G 1996 Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452.
27. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F 1994 Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189-1196.
28. Lorenzo JA, Naprta A, Rao Y, Alander C, Glaccum M, Widmer M, Gronowicz G, Kalinowski J, Pilbeam CC 1998 Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139:3022-3025.
29. Hankenson KD, Bain SD, Kyriakides TR, Smith EA, Goldstein SA, Bornstein P 2000 Increased marrow-derived osteoprogenitor cells and endosteal bone formation in mice lacking thrombospondin 2. J Bone Miner Res 15:851-862.
30. Manolagas SC, Jilka RL 1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311.
31. Cenci S, Weitzmann MN, Gentile MA, Aisa MC, Pacifici R 2000 M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J Clin Invest 105:1279-1287.
32. Daci E, Verstuyf A, Moermans K, Bouillon R, Carmeliet G 2000 Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. J Bone Miner Res 15:1510-1516.
33. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC 1998 Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 101:1942-1950.
34. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F 1994 Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189-1196.
35. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
36. Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kostenuik P, Dunstan CR, Lacey DL, Sheng JZ 2001 Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 3:197-205.
37. Ueland T, Brixen K, Mosekilde L, Mosekilde L, Flyvbjerg A, Bollerslev J 2003 Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: A cross-sectional study. J Clin Endocrinol Metab 88:1014-1018.
38. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527.
39. Khosla S, Arrighi HM, Melton LJ III, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL 2002 Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13:394-399.
40. Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C, Szalay F 2002 Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res 17:1961-1967.
41. Li Z, Hou WS, Escalante-Torres CR, Gelb BD, Bromme D 2002 Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J Biol Chem 277:28669-28676.
42. Smith AJ, Singhrao SK, Newman GR, Waddington RJ, Embery G 1997 A biochemical and immuno-electron microscopical analysis of chondroitin sulphate-rich proteoglycans in human alveolar bone. Histochem J 29:1-9.